4.06
price up icon1.50%   0.06
pre-market  Pre-market:  4.01   -0.05   -1.23%
loading
Immuneering Corp stock is traded at $4.06, with a volume of 211.38K. It is up +1.50% in the last 24 hours and up +34.44% over the past month. Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
See More
Previous Close:
$4.00
Open:
$4.05
24h Volume:
211.38K
Relative Volume:
0.18
Market Cap:
$146.10M
Revenue:
$317.00K
Net Income/Loss:
$-53.47M
P/E Ratio:
-2.1481
EPS:
-1.89
Net Cash Flow:
$-49.31M
1W Performance:
-1.69%
1M Performance:
+34.44%
6M Performance:
+97.09%
1Y Performance:
+230.08%
1-Day Range:
Value
$3.96
$4.18
1-Week Range:
Value
$3.95
$4.35
52-Week Range:
Value
$1.00
$4.60

Immuneering Corp Stock (IMRX) Company Profile

Name
Name
Immuneering Corp
Name
Phone
617-500-8080
Name
Address
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Name
Employee
54
Name
Twitter
Name
Next Earnings Date
2025-03-19
Name
Latest SEC Filings
Name
IMRX's Discussions on Twitter

Compare IMRX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
IMRX
Immuneering Corp
4.06 143.94M 317.00K -53.47M -49.31M -1.89
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Immuneering Corp Stock (IMRX) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-13-24 Downgrade Morgan Stanley Equal-Weight → Underweight
Mar-15-24 Downgrade Jefferies Buy → Hold
Mar-15-24 Reiterated Needham Buy
Mar-15-24 Downgrade TD Cowen Outperform → Market Perform
Dec-01-23 Initiated Needham Buy
Jun-26-23 Resumed Oppenheimer Outperform
Apr-19-23 Upgrade Mizuho Neutral → Buy
Apr-19-23 Upgrade Morgan Stanley Underweight → Equal-Weight
Mar-30-23 Initiated Mizuho Neutral
Feb-03-23 Downgrade Morgan Stanley Equal-Weight → Underweight
Jul-08-22 Initiated Chardan Capital Markets Buy
Apr-01-22 Initiated Oppenheimer Outperform
Jan-07-22 Initiated Piper Sandler Overweight
View All

Immuneering Corp Stock (IMRX) Latest News

pulisher
Jul 27, 2025

How strong is Immuneering Corporation company’s balance sheetCapitalize on fast-growing investment opportunities - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What makes Immuneering Corporation stock price move sharplyProven High Yield Signals - Metal.it

Jul 27, 2025
pulisher
Jul 25, 2025

What drives Immuneering Corporation stock priceFree Popular Stock Recommendations - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

What analysts say about Immuneering Corporation stockAccelerated wealth expansion - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 19, 2025

Analysts Set Immuneering Corporation (NASDAQ:IMRX) Target Price at $13.25 - Defense World

Jul 19, 2025
pulisher
Jul 18, 2025

Is Immuneering Corporation a good long term investmentSuperior stock growth - jammulinksnews.com

Jul 18, 2025
pulisher
Jul 15, 2025

Why Immuneering Corporation stock attracts strong analyst attentionShort Term Profit Focus - Newser

Jul 15, 2025
pulisher
Jul 10, 2025

Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up - Quantisnow

Jul 10, 2025
pulisher
Jul 09, 2025

Revolutionary Cancer Drug Gets Patent Protection Until 2042: Clinical Data Shows 94% Survival vs 67% Standard Care - Stock Titan

Jul 09, 2025
pulisher
Jul 07, 2025

Immuneering director Hausman buys IMRX stock worth $19,862 By Investing.com - Investing.com South Africa

Jul 07, 2025
pulisher
Jul 07, 2025

Immuneering (IMRX) chief people officer Neufeld buys $2498 in stock By Investing.com - Investing.com South Africa

Jul 07, 2025
pulisher
Jul 07, 2025

Immuneering director Hausman buys IMRX stock worth $19,862 - Investing.com

Jul 07, 2025
pulisher
Jul 01, 2025

Insider Buying: Thomas Schall Acquires Additional Shares of Immu - GuruFocus

Jul 01, 2025
pulisher
Jun 27, 2025

Immuneering (IMRX) Soars 10.66% on Positive Trial Data, Insider Buying - AInvest

Jun 27, 2025
pulisher
Jun 26, 2025

At $3.02 Price, Immuneering Corp (IMRX) Is Sitting And Waiting - Stocksregister

Jun 26, 2025
pulisher
Jun 25, 2025

Jefferies raises Immuneering price target to $3.50 from $1.50 on cancer data - Investing.com

Jun 25, 2025
pulisher
Jun 24, 2025

Insider Buying: Brett Hall Acquires Additional Shares of Immuneering Corp (IMRX) - GuruFocus

Jun 24, 2025
pulisher
Jun 23, 2025

Immuneering (IMRX) director Feinberg buys $63k in shares - Investing.com

Jun 23, 2025
pulisher
Jun 20, 2025

Immuneering (IMRX) CEO Zeskind buys $50k+ in shares - Investing.com

Jun 20, 2025
pulisher
Jun 19, 2025

Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients - Pipelinereview

Jun 19, 2025
pulisher
Jun 18, 2025

Immuneering (IMRX) Target Price Raised by Mizuho Analyst | IMRX Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Chardan Capital Maintains Buy Rating on IMRX with $13 Price Targ - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Metric Deep Dive: Understanding La Rosa Holdings Corp (LRHC) Through its Ratios - DWinneX

Jun 18, 2025
pulisher
Jun 18, 2025

Financial Analysis: TNL Mediagene (TNMG)’s Ratios Unveil Key Insights - DWinneX

Jun 18, 2025
pulisher
Jun 18, 2025

Immuneering (IMRX) Price Target Raised by Mizuho Following Positive Trial Data | IMRX Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Immuneering stock price target raised to $10 at Mizuho on cancer drug data - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Immuneering’s Positive Pancreatic Cancer Trial Data Sparks Bullish Retail Sentiment Even As Profit-Taking Cools Rally - Investing.com India

Jun 18, 2025
pulisher
Jun 18, 2025

Immuneering's Positive Pancreatic Cancer Trial Data Sparks Bullish Retail Sentiment Even As Profit-Taking Cools Rally - MENAFN.com

Jun 18, 2025
pulisher
Jun 17, 2025

Immuneering’s atebimetinibin shows positive survival data in pancreatic cancer - TipRanks

Jun 17, 2025
pulisher
Jun 17, 2025

Immuneering stock rises after positive pancreatic cancer trial data - Investing.com

Jun 17, 2025
pulisher
Jun 17, 2025

Immuneering (IMRX) Reports Promising Phase 2a Trial Results for Pancreatic Cancer Treatment | IMRX Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Pancreatic Cancer Breakthrough: New Drug Shows 94% Survival Rate vs 67% Standard Care in Phase 2a Trial - Stock Titan

Jun 17, 2025
pulisher
Jun 17, 2025

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success - insights.citeline.com

Jun 17, 2025
pulisher
Jun 16, 2025

Immuneering Corp holds annual stockholder meeting By Investing.com - Investing.com Canada

Jun 16, 2025
pulisher
Jun 16, 2025

Immuneering Corp holds annual stockholder meeting - Investing.com Australia

Jun 16, 2025
pulisher
Jun 16, 2025

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025 - The Manila Times

Jun 16, 2025
pulisher
Jun 16, 2025

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025 - GlobeNewswire Inc.

Jun 16, 2025
pulisher
Jun 13, 2025

Two Sigma Investments LP Purchases 10,126 Shares of Immuneering Co. (NASDAQ:IMRX) - Defense World

Jun 13, 2025
pulisher
Jun 12, 2025

Immuneering Co. (NASDAQ:IMRX) Stock Position Reduced by Millennium Management LLC - Defense World

Jun 12, 2025
pulisher
Jun 06, 2025

Immuneering’s (IMRX) Buy Rating Reaffirmed at Needham & Company LLC - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Needham Maintains Buy Rating on IMRX with Price Target of $9.00 - GuruFocus

Jun 05, 2025
pulisher
May 29, 2025

Full Immuneering Leadership Team Reveals Latest Pipeline Updates at Prestigious Jefferies Conference - Stock Titan

May 29, 2025
pulisher
May 15, 2025

‘Take the Plunge,’ Says Top Investor About Intel Stock - The Globe and Mail

May 15, 2025
pulisher
May 07, 2025

Oppenheimer Adjusts Price Target for Immuneering (IMRX) to $21.0 - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Immuneering (IMRX) Price Target Adjusted by Oppenheimer Analyst - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Immuneering (IMRX) Price Target Adjusted by Oppenheimer Analyst | IMRX Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

21,432 Shares in Immuneering Co. (NASDAQ:IMRX) Acquired by Marshall Wace LLP - Defense World

May 07, 2025
pulisher
May 07, 2025

Oppenheimer Adjusts Price Target for Immuneering (IMRX) to $21.00 | IMRX Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Immuneering Corp. Reports Promising Q1 2025 Results - TipRanks

May 07, 2025
pulisher
May 06, 2025

Immuneering (IMRX) Stock Rating and Price Target Update | IMRX S - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Immuneering reports Q1 EPS (42c), consensus (58c) - TipRanks

May 06, 2025

Immuneering Corp Stock (IMRX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Cap:     |  Volume (24h):